| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Severe fever with thrombocytopenia syndrome (SFTS) was first reported as an novel tick-born infection with a high-fatality rate during 2011 in China.SFTS has been reported to be endemic in Japan since 2013. Pathopysiology and treatment of SFTS is unclear. Recently,it was reported that the anti-viral drug (favipiravir)inhibits the replication of SFTS virus in mouse model. Therefore, we have conducted a multicenter non-randomized trial,in which all patients with SFTS would receive favipiravir since 2016.The results implied the efficacy and safety of favipiravir against SFTS patients. On the other hand,we analyzed atypical lymphocytes in the peripheral blood in four SFTS patients at our hospital.Atypical lymphocytes resembled plasma cells morphologically and showed a CD19+CD38+ phenotype in flow cytometry. Our result suggests that specific immunological response occurs at SFTS infection.
|
